We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $186M
1-Year Est. Return 155.23%
This Fund
S&P 500
This Quarter Est. Return
-0.89%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$136M
AUM Growth
+$33.8M
Cap. Flow
+$46.6M
Cap. Flow %
34.36%
Top 10 Hldgs %
94.17%
Holding
13
New
2
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$29.5M
2
KZR
Kezar Life Sciences
KZR
+$12.1M
3
CDTX
Cidara Therapeutics
CDTX
+$5.02M

Top Sells

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$4.46K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBIO
1
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$30.8M 22.75%
+2,437,601
New +$29.5M
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$26.5M 19.57%
2,600,410
– –
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$15.1M 11.17%
999,664
-336
-0% -$4.46K
KZR
4
DELISTED
Kezar Life Sciences
KZR
$12M 8.85%
+69,327
New +$12.1M
SNNA
5
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$11.5M 8.5%
758,610
– –
KYNB
6
Kyntra Bio
KYNB
$32.6M
$8.18M 6.03%
5,226
– –
CDTX
7
DELISTED
Cidara Therapeutics
CDTX
$7.85M 5.79%
75,440
+53,192
+239% +$5.02M
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$7.4M 5.46%
551,477
– –
EPIX
9
DELISTED
ESSA Pharma
EPIX
$4.12M 3.04%
1,084,848
– –
JNCE
10
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.06M 3%
529,965
– –
PVLA
11
Palvella Therapeutics
PVLA
$2.18B
$3.95M 2.91%
9,728
– –
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.74M 2.02%
223,457
– –
EGLT
13
DELISTED
Egalet Corporation
EGLT
$1.22M 0.9%
2,889,926
– –

Similar funds

LBC
Leigh Baldwin & Co Cazenovia, New York $186M AUM 40.09% 1-Year Est. Return
GWCM
Godshalk Welsh Capital Management Radnor, Pennsylvania $186M AUM 18.63% 1-Year Est. Return
FWM
Fingerlakes Wealth Management Ithaca, New York $186M AUM 30.5% 1-Year Est. Return
LOIP
Live Oak Investment Partners Austin, Texas $186M AUM 19.39% 1-Year Est. Return
TFA
Tranquilli Financial Advisor Clinton, New Jersey $186M AUM 18.12% 1-Year Est. Return
NCM
Northland Capital Management Virginia, Minnesota $186M AUM 16.43% 1-Year Est. Return
GPI
General Partner Inc Pittsburgh, Pennsylvania $186M AUM 25.15% 1-Year Est. Return
MWM
Melfa Wealth Management Westborough, Massachusetts $185M AUM 17.73% 1-Year Est. Return

Omega Fund Management's Q2 2018 Portfolio in Review

As of Q2 2018, Omega Fund Management held 13 positions worth $136M, up 33% from $102M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Omega Fund Management deployed $46.6M of net new capital in Q2 2018, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Translate Bio, Inc. Common Stock: 2,437,601 shares worth $30.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ObsEva SA Ordinary Shares, an estimated $4.46K trimmed.

  • Omega Fund Management's largest Q2 2018 buy was Translate Bio, Inc. Common Stock: 2,437,601 shares worth $30.8M.
  • Omega Fund Management added most to Cidara Therapeutics in Q2 2018, an estimated $5.02M increase.
  • Omega Fund Management's biggest Q2 2018 reduction was ObsEva SA Ordinary Shares, cutting an estimated $4.46K.
  • Omega Fund Management's ten largest holdings make up 94% of its $136M portfolio in Q2 2018.
  • Omega Fund Management opened 2 new positions and closed 0 in Q2 2018.
  • Omega Fund Management's portfolio value rose 33% quarter-over-quarter to $136M.

Based on Omega Fund Management's 13F filing for Q2 2018, filed 2 Aug 2018.